Cancer Treatments / Therapy Results, Survival Rates, Toxicity, Side Effects, and Hospital information for 100s of therapies at Cancer Monthly

Search Results

Your search returned 86 record(s).
Page 1 of 9 | Next Page

Sort By:

Please visit our sponsors.
Their generosity keeps Cancer Monthly in existence.

Important: Access to this information is subject to the full Cancer Monthly User Agreement .

We urge you to read this User Agreement. Below are some excerpts from this Agreement. These excerpts are provided for your convenience only and do not replace the full User Agreement:

Cancer Monthly does not provide medical or any other health care advice, diagnosis or treatment.
Cancer Monthly is provided for informational purposes only and is not a substitute for professional medical advice, examination, diagnosis or treatment.
You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to existing treatment.
You should not delay in seeking or disregard medical advice based on information in Cancer Monthly or the information below.
All the information available on the Cancer Monthly website including the information below is designed to be shared with your physician or other qualified healthcare professional
Medical information changes rapidly and while Cancer Monthly makes efforts to update its content, some information may be out of date.
No information contained in Cancer Monthly including the information below, should be used to diagnose, treat, cure or prevent any disease without the supervision of a medical doctor.

Again, your access to the information below is subject to the entire User Agreement.

More Colon Cancer Results
Alternative
Biologic therapy
Chemotherapy
Gene Therapy
Hormone Therapy
Immunotherapy
Radiation Therapy
Surgery

	Survival:	Patients:	Toxicity:	Treatment:	Hospital:	Country:	Date:
1	63.7 months	Resectable metastatic colorectal carcinoma to the liver	5	Chemotherapy Surgery	Queens Hospital Center	United States	3/2002
Treatment Details: Patients: This trial involved patients with one to three potentially resectable metastases of colorectal carcinoma to the liver. There were a total of 75 ?assessable? patients in this trial

2	52.9 months	colorectal (metastatic)	2	Biologic therapy Immunotherapy	Ospedale Civile di Avezzano	Italy	9/2006
Treatment Details: Patients: This phase II study compared two groups of patients. The group receiving the study treatment consisted of 40 people, 26 men and 14 women. The other group, historical controls, co

3	49.4 months	Resectable metastatic colorectal carcinoma to the liver	5	Surgery	Queens Hospital Center	United States	3/2002
Treatment Details: Patients: This trial involved patients with one to three potentially resectable metastases of colorectal carcinoma to the liver. There were a total of 75 ?assessable? patients in this trial

4	30.6 months	Unresectable colorectal cancer metastases to liver	5	Chemotherapy Surgery	Saint John's Health Center	United States	3/2002
Treatment Details: Patients: This Phase II study involved 185 patients with unresectable colorectal hepatic (liver) metastases that had gotten worse (i.e. progressed by CT and/or CEA levels) while these patie

5	30.0 months	unresectable metastatic colorectal cancer	3	Chemotherapy Surgery	University of Louisville School of Medicine	United States	4/2006
Treatment Details: Patients: This Phase II study involved 21 patients (8 men, 13 women, median age 55) with advanced colorectal cancer with unresectable liver metastases. All patients received chemotherapy be

6	30.0 months	Metastatic colorectal cancer	4	Biologic therapy Chemotherapy	Vall d'Hebron University Hospital	Spain	11/2007
Treatment Details: Patients: This phase II study involved 62 patients with metastatic colorectal cancer. The median age was 65 years, ranging from 43 to 78. Thirty of these patients were men, and 13 were wo

7	27.0 months	colorectal cancer with inoperable liver metastases	4	Chemotherapy	Institut Gustave Roussy	France	8/2005
Treatment Details: Patients: This Phase II study involved 28 patients with metastatic colorectal cancer with inoperable liver metastases. Seventeen patients were men, and eleven were women. The median age was

8	26.0 months	Colorectal cancer with unresectable liver metastases	4	Biologic therapy Chemotherapy	Mayo Clinic and Foundation	United States	12/2005
Treatment Details: Patients: This Phase II study involved 42 patients with colorectal cancer with unresectable liver metastases. Twenty-four patients were men and eighteen were women. Eight patients had chem

9	25.4 months	colon cancer (metastatic)	4	Chemotherapy	Geneva University Hospital	Switzerland	5/2005
Treatment Details: Patients: This Phase I/II study involved 30 patients with metastatic colorectal cancer. Twenty-four patients were men, and six were women. The median age was 58. The primary sites were co

10	23.1 months	Metastatic colorectal cancer	4	Biologic therapy Chemotherapy	Dana-Farber Cancer Institute	United States	10/2007
Treatment Details: Patients: This phase III study involved 430 patients with previously untreated metastatic colorectal cancer. These patients ranged in age from 20 to 87 years old. Treatment: Patients w

Page 1 of 9\| Next Page

DISCLAIMER: The following is a summary of some of the terms & conditions for accessing the information on this website. It is provided for convenience only. For the full terms & conditions please click here. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional medical advice, examination, diagnosis or treatment. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website. This website provides links to other websites for convenience only. Cancer Monthly is not responsible for the availability or content of these external websites, nor does Cancer Monthly endorse, warrant or guarantee the products, services or information described or offered at these other websites.